Bladder Cancer Panel
A research-focused service testing for urothelial bladder cancer (UBC)
Our genomic panel is comprehensively designed focusing on mutations found in 96% of bladder cancers, making it ideal for translational and clinical research into the disease as it only requires a non-invasive urine sample.
Bladder Cancer Detection for Research
DNA extraction
Quality control
Library preparation
NGS sequencing
Bioinformatics analysis
| Purpose |
|
| Type of test |
Genomic (gDNA) and cell-free (cfDNA) DNA genetic test – panel of 23 bladder cancer genes covering 451 somatic mutations |
| Sample type |
|
| Flexibility | Full service flexibility – contact us to find the best solution for you |
| Technology |
|
| Data output | Report – positive (with gene list) or negative |
| Indexing options |
|
| Bioinformatic analysis |
Options:
|
| Data transfer |
Secure cloud-based data transfer:
|
| Ordering information | Contact via the Informed Genomics contact form |
| Quality assurance | UKAS accredited, and ISO15189 approved laboratories |
How can Informed Genomics help your research into bladder cancer?
We can support your research as our service provides accessible, accurate, flexible bladder cancer testing options with the following benefits:
Enables easier patient recruitment for your project as a simple at home urine collection is required
Time saving and cost-effective solution
Delivers results equivalent to that of cystoscopy for all stages of bladder cancer, including both NMIBC and MIBC
Sensitive enough to allow multiple testing points from haematuria triage, through to minimal residual disease (MRD) and relapse surveillance
Offers full flexibility to suit your research requirements – send us the urine sample(s), or extract the gDNA/cfDNA in your laboratory
A control sample set is available if you wish to validate the workflow
We can help with bioinformatics or send a full report
Comprehensive gene panel information
The bladder panel targets promoter and exonic regions of 23 of the most relevant genes associated with bladder cancer.
The somatic mutations covered by the kit have been shown to detect 96% of bladder cancers in over 664 clinical samples. 1,2
Table 1: Gene list included in the bladder cancer panel
| AKT1 | ERBB2 | NRAS |
| BRAF | ERBB3 | PIK3CA |
| C3orf70 | ERCC2 | RHOB |
| CDKN1A | FBXW7 | RXRA |
| CDKN2A | FGFR3 | SF3B1 |
| CREBBP | HRAS | TERT (promoter) |
| CTNNB1 | KDM6A | TP53 |
| ELF3 | KRAS |
Clinical validation
664 urine samples were used to assess performance of the bladder cancer panel from three UK clinical cohorts. Results show that there is high detection and specificity across all stages and grades of bladder cancer. 1,2
Table 2. Sensitivity and specificity of the bladder panel across all stages and grades of bladder cancer.
| Sensitivity | Specificity | |
|---|---|---|
| pTa | 86% | 86% |
| T1 | 95% | 86% |
| T2+ | 89% | 86% |
| G1 | 76% | 86% |
| G2 | 92% | 86% |
| G3 | 92% | 86% |
| NMIBC | 89% | 86% |
| MIBC | 89% | 86% |
Figure 1: Bladder panel performance compared to cystoscopy and cytology across all grades of bladder cancer.
Technical performance
A cohort of reference samples were assessed to check the technical performance of the bladder cancer panel. Mutations across the spectrum of the panel were present in these samples and showed high sensitivity detecting over 95% of variants with a variant allele frequency (VAF) greater than 0.1%.3
Figure 2: The bladder cancer panel shows high sensitivity detecting VAFs down to 0.1%.
How was the bladder cancer test panel developed?
Prof Rik Bryan, and Dr Douglas Ward, from the Bladder Cancer Research Centre at the University of Birmingham collaborated with Nonacus to develop the Cell3 Target Bladder Cancer panel. They succeeded in producing a sequencing panel enabling researchers to sequence the tumour DNA found in the urine of bladder cancer patients to raw read depths in excess of 20,000×.
This depth of coverage provides the sensitivity and accuracy needed to offer a viable genomic alternative to flexible cystoscopy for the profiling of bladder cancer.
Hear from Prof Rik Bryan and Dr Douglas Ward how this panel was developed:
“It has been a pleasure to work with Informed Genomics over the last year or so with the implementation of our DNA-based diagnostic urine test for bladder cancer. The staff members are very knowledgeable about all aspects of such assays, from sample preservation and transport, to processing, sequencing and the bioinformatic analyses of the data outputs. This end-to-end expertise has made the transfer of our urine test from academic lab to service lab very straightforward.”
– Professor Richard Bryan
Bladder Cancer Research Centre, University of Birmingham, UK
References
2. Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification. BJU international. 2019 Sep;124(3):532-44.
3. Nonacus. GALEAS™ Bladder Datasheet v1. https://galeas.net/wp-content/uploads/2023/08/GALEAS-Bladder-Datasheet-v1.pdf. Published 2023. Accessed September 14, 2023.
Contact us to find out more about our Bladder Cancer Panel
Quinton Business Park
11 Ridgeway
Quinton
Birmingham
B32 1AF